Cyclerion Therapeutics, Inc. CYCN
We take great care to ensure that the data presented and summarized in this overview for Cyclerion Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYCN
View allLatest Institutional Activity in CYCN
Top Purchases
Top Sells
About CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at CYCN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 01
2024
|
Regina Margaret Graul |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+33.27%
|
-
|
|
Jan 01
2024
|
Peter M Hecht |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+3.82%
|
-
|
|
Dec 01
2023
|
Peter M Hecht |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+3.97%
|
-
|
|
Nov 30
2023
|
Errol B Desouza |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+39.29%
|
-
|
|
Nov 30
2023
|
Peter M Hecht |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+5.44%
|
-
|
|
Nov 30
2023
|
Terrance Mcguire |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+47.38%
|
-
|
|
Nov 30
2023
|
Steven Hyman |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Aug 09
2023
|
Terrance Mcguire |
SELL
Open market or private sale
|
Indirect |
8
-100.0%
|
$24
$3.4 P/Share
|
|
May 19
2023
|
Peter M Hecht |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+40.73%
|
$1,800,000
$8.68 P/Share
|
|
Jun 03
2021
|
Peter M Hecht |
BUY
Open market or private purchase
|
Direct |
823,170
+28.67%
|
$2,469,510
$3.28 P/Share
|
|
Jun 03
2021
|
Terrance Mcguire |
BUY
Open market or private purchase
|
Indirect |
96,153
+11.75%
|
$288,459
$3.12 P/Share
|
|
Jun 03
2021
|
Slate Path Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
961,538
+11.84%
|
$2,884,614
$3.12 P/Share
|
|
May 06
2021
|
Peter M Hecht |
BUY
Open market or private purchase
|
Direct |
302,000
+19.78%
|
$604,000
$2.43 P/Share
|
|
May 05
2021
|
Peter M Hecht |
BUY
Open market or private purchase
|
Direct |
398,001
+30.14%
|
$796,002
$2.53 P/Share
|
|
May 04
2021
|
Peter M Hecht |
BUY
Open market or private purchase
|
Direct |
300,000
+36.38%
|
$600,000
$2.29 P/Share
|
|
Feb 25
2021
|
Christopher I Wright Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,637
-5.81%
|
$7,911
$3.99 P/Share
|
|
Feb 25
2021
|
Anjeza Gjino Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,824
-5.46%
|
$7,296
$4.0 P/Share
|
|
Dec 28
2020
|
Mark G Currie President and CSO |
SELL
Open market or private sale
|
Direct |
20,107
-7.4%
|
$60,321
$3.01 P/Share
|
|
Nov 09
2020
|
Andreas Busch Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
125,000
+32.92%
|
$250,000
$2.53 P/Share
|
|
Nov 06
2020
|
William Huyett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,827
-5.36%
|
$7,654
$2.52 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 175K shares |
|---|